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Abstract
Breast tumors consist of several different tissue components. Despite the heterogeneity, most gene expression analyses
have traditionally been performed without prior microdissection of the tissue sample. Thus, the gene expression profiles
obtained reflect the mRNA contribution from the various tissue components. We utilized histopathological estimations of
area fractions of tumor and stromal tissue components in 198 fresh-frozen breast tumor tissue samples for a cell type-
associated gene expression analysis associated with distant metastasis. Sets of differentially expressed gene-probes were
identified in tumors from patients who developed distant metastasis compared with those who did not, by weighing the
contribution from each tumor with the relative content of stromal and tumor epithelial cells in their individual tumor
specimen. The analyses were performed under various assumptions of mRNA transcription level from tumor epithelial cells
compared with stromal cells. A set of 30 differentially expressed gene-probes was ascribed solely to carcinoma cells.
Furthermore, two sets of 38 and five differentially expressed gene-probes were mostly associated to tumor epithelial and
stromal cells, respectively. Finally, a set of 26 differentially expressed gene-probes was identified independently of cell type
focus. The differentially expressed genes were validated in independent gene expression data from a set of laser capture
microdissected invasive ductal carcinomas. We present a method for identifying and ascribing differentially expressed genes
to tumor epithelial and/or stromal cells, by utilizing pathologic information and weighted t-statistics. Although a
transcriptional contribution from the stromal cell fraction is detectable in microarray experiments performed on bulk tumor,
the gene expression differences between the distant metastasis and no distant metastasis group were mostly ascribed to
the tumor epithelial cells of the primary breast tumors. However, the gene PIP5K2A was found significantly elevated in
stroma cells in distant metastasis group, compared to stroma in no distant metastasis group. These findings were confirmed
in gene expression data from the representative compartments from microdissected breast tissue. The method described
was also found to be robust to different histopathological procedures.
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Introduction
Female breast cancer counts for over 465 000 deaths annually
world wide (approximately 1.300.000 new cases), and is the most
common cancer type among women [1]. Earlier diagnosis and
more efficient treatment strategies have reduced the mortality and
lowered the risk for recurrence. Established molecular markers
such as the estrogen receptor (ER), progesterone receptor (PgR)
and human epidermal growth factor receptor 2 (HER2/neu) are
considered routinely for treatment decisions [2].
Whole-genome DNA microarrays for gene expression have
made it possible to unravel biological mechanisms underlying
the disease at the transcriptomic level [3]. Microarray experi-
ments allow for measurements and comparisons of gene
expression within a sample as well as between multiple samples.
For example, gene expression profiling has shown that breast
tumors can be classified into subgroups displaying distinct
characteristics with respect to both clinical markers and patient
outcome [4–7], which emphasizes that breast cancer is a
heterogeneous disease that should be treated accordingly.
Specific gene signatures have been identified that correlate with
different aspects of the disease, including two risk-predictors for
distant recurrence that are currently being tested in large clinical
trials [8–12].
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environment of various cell types both within the tumor area and
in the surroundings. Lymphocytic infiltrations, fibrosis, angio- and
lymphanogenesis, and stromal cells (including fibroblasts, myofi-
broblasts and adipocytes), leukocytes, and myoepithelial cells may
influence the development and further progression of the
carcinoma cells [13]. Although there are studies showing that
alterations and involvement of the microenvironment (stromal
tissue) of breast carcinomas influence outcome [14,15], most gene
expression analyses have been performed using the bulk tumor,
without further reference to the stromal content. Hence, without
performing any cell selection (by microdissection) prior to gene
expression analysis, the output data have contained transcriptomic
information from all tissue components in the sample. The
variable contribution from different cell fractions makes it difficult
to state whether differences in gene expression between samples
arise from distinct expression within the same cell type, and/or
reflect the diversity in gene expression between various types of
cells [16].
Cleator and colleagues [17] showed, using gene expression
microarray analysis, that the stromal component of breast
carcinomas influenced the prediction of therapy response. They
emphasized the significant effect the non-tumor-cell content of
breast cancer samples has on gene expression profiles. Further-
more, in a study of prostate cancer, Stuart and colleagues [18]
linked, in silico, the relative content of tumor cells, benign
hyperplastic epithelium, stroma, and dilated cystic glands in 88
prostate specimens to gene expression levels determined by
microarray analysis. They were able to identify gene expression
differences between non-malignant and malignant epithelial
cells without being confounded by the gene expression of
stromal cells. Since the content of tumor cells varies between
patient samples, a threshold for minimum content of tumor cells
within a sample is often applied. Such a threshold is quite
arbitrary and would exclude potentially important cell type
interactions.
In this study we utilized the histopathological information of
tumor epithelial cell and stromal cell area-fractions to perform cell
type-associated gene expression analyses of primary breast tumors.
We compared a group of breast cancer patients who experienced
distant metastasis (DM) with a group who experienced no distant
metastasis (NoDM) during a median follow up period of .15
years. In this approach, using tumor epithelial cell-based weights, a
sample where these cells cover a small percentage of the area of
the tissue sample, will contribute less than a sample where tumor
cells are more abundant when investigating gene expression
differences originating in tumor tissue. We provide here an in silico
method to ascribe differentially expressed gene-probes (DEGs) in
primary breast tumors between patients experiencing DM and
patients experiencing NoDM to either tumor epithelial and/or
stroma cells.
Results and Discussion
Initially a standard t-test was performed, referred to as the ‘‘un-
weighted analysis’’, between the DM and NoDM tumor groups in
a set of primary breast tumor samples from 198 patients. Clinical
characteristics are given in Table 1. The un-weighted test
identified 182 differentially expressed gene-probes (DEGs) at a
5% FDR level (Table S1’’). This gene-probe list was in the
following referred to as the UWA-list (Un-weighted analysis-list).
Similar results were obtained when using variations of the t-
statistics, as presented by Tusher and colleagues [19].
Testing the relationship between cell area fraction and
overall expression
For every tumor sample, histopathologic information regarding
the content of different tissue components (tumor epithelium,
stroma and adipocytes) was available (see Materials and
methods).The distribution of the different tissue components was
not significantly different (p-value 0.78 for tumor epithelial cells
and 0.87 for stromal cells, Kolmogorov-Smirnov two-sample test)
between the DM and noDM groups (Figure 1).
In order to test if the pathological numbers of the area fraction
of tumor epithelial and stromal cells made an impact on the
expression data we collected a list of genes reported to be stromal
or tumor cell related in breast cancer by literature search [17,20].
Two methods were applied to see how the expression of these
genes was related to the pathological numbers in our data. In the
first approach, we compared gene expression data from the 15
tumor pieces having the highest stroma cell area-fraction with the
expression data from the 15 tumor pieces having the highest tumor
epithelial cell area-fraction. By doing a SAM [19] between the
high tumor epithelial cell - and high stroma cell area fraction
samples, we obtained one list of genes whose expression were
elevated in the samples with high tumor epithelial cell area-
fraction (list A), and one list of genes whose expression were
elevated in the samples with high stroma cell area-fraction (list B).
In the second approach we calculated the Pearson correlation
between the gene expression for all genes and the mean centered
pathological numbers for stromal (list C) and tumor epithelial cell
area-fractions (list D) (across all 198 samples). The majority of the
genes extracted from the literature were confirmed in our data,
Table 1. Clinical information.
DM NoDM
p- value Parameter No. % No. %
All 118 60 80 40
0.692 Protocol b CMF 55 47 35 44
Protocol c TAM 63 53 45 56
0.105 Radiotherapy YES 54 46 46 58
NO 64 54 34 42
0,054 Tumor Sixe ,20 mm 32 27 30 38
20–50 mm 64 54 44 55
.50 mm 22 19 6 7
0.000 Pos lymph nodes None 8 7 3 4
1–3 43 36 62 77
.3 6 75 7 1 51 9
0.002 Histopathology Ductal 90 77 63 86
Nonductal 28 23 17 14
0.004 Malignancy Grade 1 17 19 17 27
(Ductal-only) Grade 2 42 47 39 62
Grade 3 31 34 7 11
0.008 ER-status Neg 39 33 13 16
Pos 79 67 67 84
Unknown 0 0 0 0
The null hypothesis is that the probabilities for each outcome (DM or noDM) are
independent of the state or treatment (as written in the column).
One sided Chi-square or Fisher exact test for 2 by 2 or 2 by three contingency
tables.
doi:10.1371/journal.pone.0014002.t001
Weighted Gene Expression
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was robust (see Table S2). This indicates that both tumor stroma
and tumor epithelial cells contribute a measurable amount of
mRNA transcripts into the gross gene expression signal from the
bulk tumor. We were not able to identify any candidate markers
for adipocytic expression.
Robustness with respect to histopathology
The histopathological numbers utilized in the weighted analyses
were crude estimates of area-fractions of tumor epithelial, stroma
and adipocytic cells. In order to assess the robustness of the
weighting approach in relation to the histopathological procedure,
stereological point counting was performed additionally on a
representative selection of the tissue sections. The numbers of area
fraction from the stereological point counting were then utilized to
calculate new weights for the sub-selection of samples. The new
weights were compared to the initial weights used in the analyses.
If the weights from the two methods were significantly different,
then the output from the analyses would depend on the
histopathological method applied. The first step of the validation
was to test if the 109 samples selected for stereological point
counting were representative for the whole set of 198 samples.
None of the three statistical tests which compared the mean area-
fraction for tumor epithelial, stroma and adipocytes respectively in
the two sets of samples were found to be significant. Therefore we
concluded that the 109 samples were representative for the whole
data set. The second step was to compare the area-fraction
numbers of tumor-epithelial, stroma and adipocytes in the 109
samples common for the two histopathological procedures. The
differences in area fractions between the two procedures were
highly significant for all three area fractions estimated. The
stereological point counting tended to give a lower scoring of
tumor epithelium and adipocytes and a higher scoring of stroma
area-fraction, compared to the initial histopathological estimates.
Hence, these tests revealed significant differences in the exact area
fraction values measured with the two methods which are in
accordance with previous publications determining that semi-
quantitative measurements tend to produce an overestimation as
compared to stereology [21]. However, in the weighted analyses it
is not the proportion of tumor epithelial versus stroma cell area
fraction within one sample that is important. But rather how the
numbers of tumor epithelial and stroma area-fraction in the
individual samples are in respect to the total number of tumor
epithelial and respectively stroma area-fraction in all samples (in
this case the group of individuals who did or did not experience
DM). Therefore, new tumor and stroma weights were computed
Figure 1. Cell type distribution between outcome groups. The density of the data was estimated by kernel smoothing where each point on
the curve gives the probability (on the y-axis) of observing a given value x (of the x-axis). Percentages of the area of H&E sections of three different
tissue components; tumor epithelial cells, stromal cells and adipocytes, grouped by clinical group. (DM=distant metastasis; NoDM=no distant
metastasis).
doi:10.1371/journal.pone.0014002.g001
Weighted Gene Expression
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counting. Then the weights were re-scaled by setting the level of
transcription of adipocytes to null as described in the ‘‘statistical
methods’’ section. The new weights were compared to the original
ones in a paired t-test. The obtained p-values for the paired t-test
were close to one for both the tumor and stroma weight
comparisons, indicating no differences between the weights
derived from the two histopathological approaches. Hence, it
appears from these analyses that the weighting method is robust to
variations in histopathological procedures.
Weighing under different assumptions of adipocyte
transcription
The level of transcriptional contribution from adipocytes,
compared to tumor epithelial and stromal cells in a heterogenous
compartment is uncertain. Therefore, the statistical analyses were
first carried out under various assumptions on the relative
transcriptional efficiency of adipocytes compared to the two other
tissue components. In the first series of analyses, DEGs between
the DM and NoDM groups were identified under two different
assumptions of mRNA levels in adipocytes (denoted by c): Firstly,
we assumed that total adipocyte transcription level was equal to
stroma cells and tumor epithelial cells (c=1); secondly, we assumed
no transcription in adipocytes (c=0). The weighted analyses were
divided into tumor-focused analyses (TFA) and stroma-focused analyses
(SFA). In TFA, each sample was weighed proportionally to the
area fraction tumor epithelium of that tumor sample, while in
SFA, by the stromal cell percentage of that tumor sample. Thus,
higher impact in the statistical analysis was given to samples
containing more tumor epithelium or stromal cells, respectively.
The TFA and the SFA respectively returned 169 and 77 DEGs,
under the assumption of no transcription in adipocytes (c=0).
When the adipocyte transcription was weighed equally as for
tumor epithelium and stroma (c=1), the numbers of DEGs found
between DM and NoDM tumor groups were 169 in the TFA and
85 in SFA, respectively (Figure 2). All the DEGs were obtained
after multiple testing adjustments (5% FDR).
There were several overlapping gene-probes in the lists of
DEGs. Fourty-five gene-probes were found in common between
UWA and the lists from both weighted analyses (TFA and SFA)
when c=0. An identical number of overlapping probes between
UWA and the weighted analyses were also identified under the
assumption of c=1(Figure 2). The intersection of these two core
sets of 45 gene-probes was 31. Hence, these 31 gene-probes were
identified by the UWA as well as the SFA and TFA under both
assumptions on adipocyte transcription (c=0and c=1) and were
among the most differentially expressed gene-probes between the
two outcome groups. In addition, most of the 182 probes in UWA
(representing 181 different genes) were also detected in the
weighted analyses (141 for c=0and 138 for c=1). The remaining
probes (41 and 44 when c=0 and c=1, respectively) were not
identified in the weighted analysis at 5% FDR but appeared as
significant at 10 or 20% FDR. It is interesting that both the TFA
and SFA identified probes that appeared as statistically non-
significant in the standard un-weighted analysis. These were 48
and 55 tumor-associated probes (when c=0, and c=1, respec-
tively) and 12 and 16 stroma-associated probes (for c=0and c=1,
respectively) (Figure 2).
Lists of DEGs identified through weighing by tumor epithelium
and stroma content were then generated separately for other
various assumptions of adipocyte transcription levels from c=0to1
(c=0, 0.2, 0.4, 0.6, 0.8 and 1). In summary, in the TFA there were
105 DEGs which appeared for all the selected adipocyte
transcription levels (tumor associated consensus-list with adipocyte
transcription, TACat ) (Figure 3), while there were 38 DEGs in the
stroma consensus list (stroma associated consensus with adipocyte
transcription, SACat) (Figure 4). Based on these analyses and the
comparison of all generated lists of DEGs under various
assumptions of adipocyte transcription level, we decided to
proceed the analyses with c=0, as the impact on the differentially
expressed gene-probes between DM and noDM under the various
assumptions on adipocyte transcription was minor.
Weighing under different assumptions of stromal cell
transcription
Even though the contribution from fat cells on transcriptional
differences between two outcome groups in our analyses seems to
be minimal, this may not be the case for stromal cells. In fact, it
has been suggested that genes expressed in tumor-related stroma
may predict disease outcome for breast cancer patients [15]. In the
next series of analyses of differentially expressed gene-probes
between tumors from patients experiencing DM or NoDM during
follow up, we performed both tumor-epithelium-focused and
stroma-focused analyses under various assumptions on mRNA
level from the stromal compartment. Similarly to the above
analyses, we varied the stromal expression strength d, in five
intervals from 0.2 to 1 (d=0 was not selected as it would be
equivalent to the UWA), and identified five lists of DEGs in the
tumor-weighted analysis (Figure 5). If the true stromal transcrip-
tion level (compared with tumor epithelium) was known, the list of
DEGs identified using the true d would be selected. Since the true
d is unknown, these five lists were interpreted together. When
d=1, stromal and tumor epithelial cells were assumed to have
equal levels of mRNA transcription. In the tumor-focused
analyses, the contribution of each sample then equaled the
samples’ tumor epithelium percentage. For each selected value of
d, the individual sample weights were re-scaled (see Materials and
methods). A low value of d assumes low mRNA transcription level
Figure 2. Overlap of differentially expressed gene-probes for
different assumptions of adipocyte transcription. The Venn
diagrams illustrate the sets of differentially expressed gene-probes with
their intersections. The number of probes are given in each set,
identified in unweighted (blue), tumor-focused (red) and stroma-
focused (grey) analyses, respectively, when adipocytes contribute no
transcript (c=0), and when adipocytes contribute equally to tumor and
stroma cells (c=1).
doi:10.1371/journal.pone.0014002.g002
Weighted Gene Expression
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sample was therefore increased in a TFA and decreased in a SFA.
For different values of d, the re-scaling of the weights gives
stronger impact to samples with a high stroma percentage in a
TFA as d is selected from 1 towards 0.2, since a low d assumes that
the mRNA transcription mainly comes from tumor epithelial cells.
Hence, the list of gene-probes from the TFA when d=1 is less
likely to contain DEGs originating from stromal tissue than when
d=0.2, because samples that consisted of mostly tumor epithelial
cells counted more in the TFA when d=1. Finally, in order to
distinguish DEGs most likely to originate from tumor epithelium,
we need to subtract the DEGs identified in the TFA with the
DEGs identified in the SFA.
A set of 94 DEGs (tumor associated consensus-list stroma
expression varied, TACsev) was identified regardless of the
assumption on the level of stroma cell transcription d (Figure 5).
The TACsev-list is less likely to contain DEGs originating from the
stromal compartment since it includes the DEGs identified with
d=1.
Further, in the stroma-weighted analysis, again under various
assumptions on the level d of transcription from stromal cells, the
number of DEGs varied as d was increased from 0.2 to 1. Here, a
set of 31 DEGs (stroma associated consensus list stroma expression
varied, SACsev) was always identified regardless of the assumption
on the level of transcription of stromal cells (Figure 6). The SFA is
less prone to identify DEGs originating from tumor epithelial cells,
Figure 4. Differentially expressed gene-probes identified in the stroma-focused analysis for various assumptions of adipocyte
transcription. In the stroma-focused analysis, a set of genes for each assumption of c was identified and a consensus list of 38 probes was
determined. Red boxes: up in DM ; Green boxes: up in NoDM. (SACat - stroma associated consensus with adipocyte transcription).
doi:10.1371/journal.pone.0014002.g004
Figure 3. Differentially expressed gene-probes identified in the tumor-focused analysis for various assumptions of adipocyte
transcription. A set of DEGs was identified from each of six analyses for different assumptions of c. A consensus list of 105 probes was categorized.
Red boxes: up in DM ; Green boxes: up in NoDM. (TACat - tumor associated consensus-list with adipocyte transcription).
doi:10.1371/journal.pone.0014002.g003
Weighted Gene Expression
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analyses, a sample counted more if it consisted of more stroma
(and hence less tumor cells) while it counted less if there were few
stromal cells and proportionally more tumor epithelium, for each
d from 1 to 0.2.
One of the values of d should be close to reflecting the true
stromal contribution, but as this is unknown and SACsev represents
the intersection of all the selected values of d, we expect most true
DEGs to be in this list. These DEGs are likely to originate from
stromal cells; if the same DEG also appears in TACsev, it could be
an indication that the tumor focused analyses wrongly ascribed the
differential expression of this gene-probe to tumor cells. The
DEGs in TACsev that are not in SACsev are hence more likely to be
tumor epithelial cell-related. Because of these conceptual aspects,
we focused on the identified DEGs that composed the intersections
(consensus lists) from the analyses based on all 5 values of d
(TACsev and SACsev), since these are most likely to withhold the
true d (assuming the stroma transcription level was not less then
,20% of tumor cell transcription level, as a conservative
hypothesis) (Figure 7). We interpret these gene-probes as the most
robustly identified DEGs between the DM and NoDM group, and
the most biologically interesting. Finally, one important issue is
that gene-probes whose expression profiles show extreme differ-
ences originating from tumor cells between the two outcome
groups, might still have been identified in the stroma focused
analyses even if tumor epithelium contributed less (and vice versa).
Biological interpretation of the consensus gene lists
We identified 68 DEGs in TACsev (94 DEG-list) that were not
identified in SACsev (31 DEG-list). However, 38 of the 68 DEGs
were identified by one or more of the stroma weighted analyses
under different assumptions of stromal transcription level and
could therefore not be ascribed exclusively to tumor epithelial cells
(Figure 7). These 38 DEGs are therefore referred to as ‘‘tumor cells
associated’’. We do propose that the differences in expression
between DM and NoDM for the remaining 30 unique gene-
probes in TACsev descended from tumor cells, since these were not
identified by any of the five stroma weighted analyses. Among
these were the insulin-like growth factor 1 receptor (IGF1R),
cAMP responsive element binding protein-like 2 (CREBL2), and
RAB31, member RAS oncogene family (RAB31).
Figure 6. Differentially expressed gene-probes identified in the stroma-focused analysis for various assumptions of stroma
transcription. For various assumptions on stromal cell contribution, a set of DEGs was identified. C=0 for these analyses and the area of tumor and
stroma cells was re-scaled to sum to 100. A consensus list of 31 probes was determined. Red boxes: up in DM ; Green boxes: up in NoDM. (SACsev -
stroma associated consensus list stroma expression varied).
doi:10.1371/journal.pone.0014002.g006
Figure 5. Differentially expressed genes identified in the tumor-focused analysis for various assumptions of stroma transcription.
Similarly, a set of DEGs was identified for each of six tumor-focused analyses, under various assumptions on the contribution of transcripts from
stroma. A consensus list of 94 probes was determined. C=0 for these analyses and the area of tumor and stroma cells was re-scaled to sum to 100.
Red boxes: up in DM ; Green boxes: up in NoDM. (TACsev - tumor associated consensus-list stroma expression varied).
doi:10.1371/journal.pone.0014002.g005
Weighted Gene Expression
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stroma cells since there were no DEGs between DM and NoDM
that were not identified in at least one of the tumor-focused
analyses (i.e. TACsev). In fact, four out of five SACsev gene probes
not found in TACsev were still identified by four out of five tumor
focused analyses when the contribution of stroma expression was
varied (Figure 7). The fifth gene, phosphatidylinositol-4-phosphate
5-kinase, type II, alpha (PIP5K2A) was only identified by one of the
five TACsev-analyses. These DEGs are therefore referred to as
‘‘stroma cells associated’’. However, it is interesting to note that
these genes were identified by the tumor focused analyses for the
lower values of d, hence, differences in gene expression from these
five genes, and PIP5K2A in particular, might mainly be associated
to stromal cells. PIP5K2A is part of the v-akt murine thymoma viral
oncogene homolog 1 (AKT1) signaling pathway [22] and was
higher expressed in tumors from patients who experienced distant
metastasis. PIP5K2A has been reported to be involved in
differentiation and motility; hence it might influence the metastatic
process. The remaining four DEGs of the SACsev list that were not
in TACsev were flavin containing monooxygenase 5 (FMO5),
isovaleryl Coenzyme A dehydrogenase (IVD), leucine rich repeat
containing 46 (LRRC46), and double C2-like domains, alpha
(DOC2A), all found to be lower expressed in the DM group.
Longer relapse-free survival has previously been reported for
patients with higher expression of FMO5 [23] which is in line with
the observed expression of FMO5 in our study. Isovaleryl-CoA
dehydrogenase (IVD) is a mitochondrial matrix enzyme that
catalyzes the third step in leucine catabolism, and was found to be
lower expressed in rats injected with estradiol valerate [24], which
might indicate that this gene is downregulated by estrogen. In our
study, IVD-expression was lower in the DM-group, in which
tumors also showed lower expression of estrogen receptor 1 (ESR1)
when compared to the NoDM group. It is on the other hand,
questionable how comparable these two studies are. Regarding
LRRC46, a recent study reports that this gene was expressed higher
in estrogen receptor positive breast cancer tumors which are
comparable to what was observed in our study [25]. DOC2A was
reported to be highly expressed in brain cells where the protein
was found to interact with Ca2+ and phospolipid in neurotrans-
mission [26], and to our knowledge, no apparent connection
between this gene and metastasis in breast cancer has previously
been reported. There were two different DOC2A-probes present on
the microarray used in this study, and only one of these showed
significant difference in expression between the DM and NoDM
groups. These probes might represent different splice variants, and
need to be further validated.
There were 26 DEGs in common between the two consensus
lists of DEGs (TACsev, and SACsev) (Figure 7). We consider these
probes most robust in being differentially expressed between DM
and NoDM since they are identified in every instance of cell type
focus under different assumptions of stroma transcription. Among
these 26 probes we did find known breast cancer related genes
such as Arylamine N-acetyltransferase-1, (NAT1) [27], and v-myb
myeloblastosis viral oncogene homolog (MYB), both reported
earlier as a potential prognostic markers in estrogen receptor
positive breast tumors [28]. Both NAT1 and MYB were found to be
lower expressed in the DM group in our data. Another gene of
interest (also lower expressed in DM) is the zinc finger, MYND-
type containing 10 (ZMYND10) gene, which has been suggested to
act as a tumor suppressor gene in nasopharyngeal carcinomas
[29]. All 26 DEGs in common between TACsev and SACsev lists
were also found by the UWA. This is as expected since the criteria
of the 26 gene list is that the DEGs were identified by all values of
d in both TFA and SFA, also including the TFA with d=0,2, a
test being close to the UWA. Thus, the expression differences
between the DM and NoDM groups for these probes seem to be
sufficient to overshadow the weighing by either cell type.
Conceptually, the cell type ascription of these DEGs could be
explained by different scenarios; a) ascribed to tumor epithelial
cells assuming the expression of tumor epithelial cells overshadows
any effect of stroma; b), ascribed to stromal cells by assuming the
expression differences in stroma were adequately profound to be
detectable in a stroma focused analysis at low values of d (stroma-
weighted test with d=0,2) or c) these genes are differentially
expressed between DM and NoDM in both cell type compart-
ments. Analysis of expression differences for these genes in the
validation data set indicates that a) is the most likely scenario of the
three. However, we did validate one gene (ABAT) that was
significantly differentially expressed between DM and NoDM in
both tumor epithelial and tumor stroma.
Overlap between weighted and un-weighted tests
A total of five probes were identified in the consensus lists from
the weighted analyses that were not among the DEGs from the un-
weighted statistics (Figure 8). One probe from SACsev list
(PIP5K2A), and 4 probes from the TACsev list (FLJ90396, PRPF39,
Unassigned with homology to Rab22, and MAPRE2). MAPRE2
(microtubule-associated protein, RP/EB family member 2) was
found highly expressed in the DM group, and has been suggested
(due to homology) to be involved in tumorigenesis of colorectal
cancers and proliferation control in normal cells [30]. There is no
reported function for the remaining three genes. Furthermore, we
identified 88 probes (representing 88 genes) in UWA which were
neither in TACsev nor SACsev. However, when we considered all
312 DEGs identified in the weighted analyses for all values of d
between 0,2 - 1, there were 137 genes that were not present in the
182 UWA-list, and conversely, only 6 probes (6 genes) in the UWA
list that were not present in any list from the weighted analyses (see
Table S3).
Validation
In order to validate the tumor stromal and tumor epithelial
ascribed (and associated) gene expression differences between the
DM and NoDM groups, the expression of the genes in the
consensus gene list (Figure 7) was tested in an independent data
set. In the validation set, tumor epithelial cells and tumor stroma
cells from 50 and 61 breast cancer patients, respectively, were
isolated using laser capture microdissection (LCM) [15].
To assess the differences in expression of each gene between the
DM and NoDM group a simple t-test was utilized. Out of the 30
tumor ascribed DEGs (in figure 7) 21 had available gene
expression in the tumor-epithelial LCM validation set. Seven out
Figure 7. Differentially expressed genes in TACsev and SACsev identified by the weighted analyses. The most repeatedly identified
probes in either every tumor focused analysis or every stroma focused analysis for different values of d (assumed stromal transcription level). The ‘#tf’
and ‘#sf’ columns list in how many tumor focused and stroma focused analyses, respectively, the corresponding DEGs were identified. The colored
vertical bar goes from darker blue (highly tumor associated) to lighter blue as the DEGs are identified in more stroma focused analyses (for different
values of d), to green for DEGS found in both SFA and TFA, and finally yellow for stroma associated DEGs identified in fewer tumor focused analyses.
Red boxes: up in DM ; Green boxes: up in NoDM.
doi:10.1371/journal.pone.0014002.g007
Weighted Gene Expression
PLoS ONE | www.plosone.org 10 November 2010 | Volume 5 | Issue 11 | e14002of the 21 genes were found significantly differentially expressed
(p,0.05) between DM and NoDM patients in the validation set
with coherent up and downregulation in the respective clinical
groups. Nine additional genes showed up and downregulation in
the same direction as what was found in the initial analyses
compared to the initial analyses. However, these genes did not
reach significant p-values in the validation set (0.05,p,0.5). The
remaining 5 genes showed no difference between DM and NoDM
(see Table S4).
Out of the 38 tumor associated DEGs 29 had available gene
expression in the tumor-epithelial LCM validation set. Eight out of
the 29 genes were found significantly differentially expressed
(p,0.05) between DM and NoDM patients in the validation set
with coherent up and downregulation in the respective clinical
groups compared to the initial analyses. Fourteen additional genes
showed up and downregulation in the same direction as what was
found in the initial analyses. However, these genes did not reach
significant p-values in the validation set (0.05,p,0.5). The
remaining 6 genes showed no difference between DM and NoDM
(one gene had non-significant opposite regulation in the validation
set).
Out of the 26 overlapping DEGs 19 had available gene
expression in the tumor-epithelial LCM and the tumor-stroma
validation sets. Eight out of the 19 genes were found significantly
differentially expressed (p,0.05) between DM and NoDM
patients in the tumor-epithelial validation set. The eight genes
had coherent up and downregulation in the respective clinical
groups compared to the initial analyses. Six additional genes
showed up and downregulation in the same direction as what was
found in the initial analyses. However, these genes did not reach
significant p-values in the validation set (0.05,p,0.5). The
remaining 5 genes showed no difference between DM and NoDM
(one gene had non-significant opposite regulation in the validation
set). In the tumor-stroma validation set, one gene (ABAT) was
found significantly differentially expressed (p,0.05), and was
among the eight significant genes in the tumor-epithelial set. Eight
genes showed up and downregulation in the same direction as
what was found in the initial analyses. However, these genes did
not reach significant p-values in the validation set (0.05,p,0.5).
The remaining 10 genes showd no difference between DM and
NoDM (one gene had non-significant opposite regulation in the
tumor-stroma validation set).
Out of the five stroma ascribed genes, one gene (PIP5K2A) was
found significantly differentially expressed in the tumor-stroma
validation set. This gene was not significantly differentially
expressed in the tumor-epithelial validation set. Thus, the
PIP5K2A seem to be validated as a gene being significant
differentially expressed in the tumor-stroma cells but not in tumor-
epithelial cells of DM vs NoDM patients. This differentially
expressed gene was also the most stroma related as it was only
identified for one value of d in the tumor focused analyses
(Figure 7). One gene (LRRC46) was found significantly differen-
tially expressed in the tumor-stroma validation set but in the
opposite direction of the initial analysis. The expression values of
this probe had low variance in the validation set, and might not be
a functional probe (Table S4).
Impact of weighing
The unweighted approach returned a list of DEGs in which
there were varying numbers of false positives at any chosen FDR.
When the statistics was weighed by cell type content under various
assumptions of transcription levels in adipocytes and stromal cells,
we identified a set of re-occurring genes that were differentially
expressed between the DM and NoDM group. DEGs identified
under different statistical scenarios appear more robust and are
more likely true positives. However, the effect of weighing samples
differently in the analyses is similar to decreasing the sample size of
the dataset, since each sample count less than 1. Hence, some of
the differences among the lists of DEGs could be due to a sample
size effect and not the weighing it-self. The different assumptions
on transcription levels in adipocytes showed a miniscule impact on
the numbers of identified DEGs, and were thus set to zero,
although we acknowledge that there are studies emphasizing the
importance of adipocytes in breast cancer [31,32].
It should be noted that we, on the basis of weighing, can not
state whether or not a gene is expressed to a higher extent in
tumor epithelial cells compared to stromal cells. We merely
propose to which cell type the expression differences (between DM
and NoDM) of a gene could be ascribed or associated.
Conclusions
We present an in silico method for utilizing histopathological
information on tissue content of tumor biopsies in the statistical
calculations of differentially expression of genes in microarray
data. This approach was used to identify genes significantly
differentially expressed between tumors from patients who
experienced distant metastasis and tumors from those who did
not. The weighted analyses were utilized to ascribe and associate
gene expression differences between the two patient groups to
tumor epithelial and stromal cells. Although the stromal
transcription contribution was measurable in data obtained from
grossly dissected tumor tissue, the differences in gene expression
Figure 8. Overlap of differentially expressed gene-probes for
the consensus lists (SACsev and TACsev) and UWA. The overlap
of probes identified by the unweighted analysis and the intersection of
all tumor weighted analyses and stroma weighted analyses with values
of d from 1 to 0.2, under the assumption of no transcription in
adipocytes. The majority of genes, 64 of the 68 tumor cell ascribed (30)
and associated (38), and four of the five stromal cell associated are
identified in the UWA.
doi:10.1371/journal.pone.0014002.g008
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epithelial cells, and the majority of these genes can also be
identified by the unweighted bulk tumor expression. The analyses
also aided in identifying a set of core genes which seems to be
profoundly different in their expression patterns between the two
groups, independent of the cellular constitution. Thus, genes
reappearing in the weighted analyses under different assumptions
of cellular contribution to the overall transcription level have a
higher probability of being true findings.
Materials and Methods
Ethics statement
The study was approved by the national ethics committee
(Ethical Commitee for Aarhus county) and by ‘‘Datatilsynet’’ (The
Data Inspectorate - an independent administrative body under the
The Ministry of Government Administration and Reform). Oral
informed consent was mandatory, and a procedure approved by
the ethical committee at that time (1982–1987).
Patient material
The 198 breast tumor samples with high quality gene expression
data utilized in this study were part of 267 fresh frozen tumor
samples (stored at 280uC in Denmark) available after total
mastectomy surgery. The tumor samples were originally stored for
the purpose of estrogen receptor staining in the Danish Breast
Cancer Group 82 b and c cohort (DBCG82b&c). DBCG82 b and
c studies comprise a collection of tumor tissues from 3,083 high-
risk Danish breast cancer patients diagnosed in the period 1982–
1990. High-risk was defined as positive lymph nodes and/or
tumor size larger than 5 cm and/or invasion of tumor to
surrounding skin or pectoral fascia. Total mastectomy with partial
axillary dissection was performed on all women, and a median of
seven lymph nodes was removed from the axilla.
Premenopausal women (DBCG b protocol) were randomized to
receive radiation therapy and CMF (cyclophosphamide, metho-
trexate, fluorouracil; eight cycles) or only CMF chemotherapy (9
cycles) [33]
Postmenopausal women (DBCG c protocol) were randomized
to receive radiation therapy+tamoxifen (30 mg daily for 1 year) or
tamoxifen alone
Follow-up
Patients were followed routinely at regular intervals the first 10
years or until the first recurrence, death or new primary cancer.
Recorded endpoints were locoregional recurrence (LRR), distant
metastases (DM) and contralateral breast cancer (CBC) [34].
Sample handling
Fresh frozen tumor samples (approximately 5–10 mm
3) from a
subset of 267 out of the 3,083 patients in the DBCG82 b and c
protocols were available for this study. All tumor samples were cut
in three and the centre section was used for total RNA extraction
whereas the two flanking pieces were used for histopathological
analyses using Haematoxylin & Eosin (HE) staining (Figure S1).
Approximately 40 mg of tissue was used for total RNA extraction
using the Qiagen Midi kit Extraction column procedure (Qiagen)
after homogenisation using the Mixer Mill (MM301, Retsch).
RNA quality was assessed using the NanoDrop instrument
(concentration and purity), and the Agilent Bioanalyser instrument
(degradation). Samples showing a degradation factor .20% were
excluded from further analyses: the remaining 218 RNA samples
of good quality were stored at 280uC.
Histopathology
Haematoxylin & Eosin (HE)-stained sections were prepared
from the two flanking tissue pieces facing the centre section used
for RNA extraction (Figure S1), and HE sections were used for
evaluating the cellular composition of the tissue sample. The tissue
components evaluated were: 1) stroma, primarily comprising
tumor-related stroma but also normal, surrounding stroma
including vessel walls and lymphocytes. 2) epithelium, comprising
tumor epithelium and possible normal epithelium entrapped in the
tumor area or lying subjacent to the invasive component, and
finally, 3) adipocytes entrapped in or surrounding the tumorarea.
The area fractions from two sections per patient sample were
estimated by a pathologist (JMN), and validated by stereological
point counting [35]. A grid consisting of 20–70 points (depending
on size of the tissue sample) were superimposed on each tissue
section using a projection microscope and the entire section was
evaluated by moving the grid in a random, systematic way. Hits on
folds, not allowing proper morphological recognition of the
structures, were excluded. Area fractions were calculated as
number of points hitting profiles divided by total number of tissue
points.
Most sections were entirely comprised of invasive tumor, and in
these the amount of normal tissue stroma was negligible.
Microarray analysis
The microarray system used in the study was the Applied
Biosystem Human Genome Survey Microarray version 2.0. These
are whole genome arrays spotted with 32878 probes covering
29098 genes. The platform utilizes chemiluminescence labeling in
a single channel system. The probes are 60-mers, mostly mapped
within 1500 bases of the 39 end of the source transcript, and were
designed to match common regions of multiple alternative
transcripts for a particular gene. For some genes there are
multiple probes, although 87% of the genes are targeted by a
single probe. In addition to the human gene probes, the
microarray contains numerous internal control probes for
monitoring the experimental steps in the amplification, labeling
and hybridization procedure. A second set of control probes is
present for intra array normalization purposes (spot to spot
normalization). These probes are 20-mers printed alongside the
gene-probes in every spot. The shorter control-probes are
complementary to a fluorescently labeled control sequence that
is added to the hybridization solution. The fluorescent signal
emitted should be identical for every spot; the gene-spot signal is
normalized parallel to the difference in the fluorescent signal in the
same spot compared to all the other spots [36]. 500 ng of total
RNA was used as input in the amplification and labeling
procedure and 10 mg of labeled and amplified cRNA was
hybridized onto the array for 16 hours followed by washing and
signal detection. Twenty arrays were removed due to too low
present call or failed out on the amplification efficiency control
probes, 7 samples with no available histopathology were excluded
from the weighted analyses (but included in the unweighted) giving
a total of 191 unique samples with good quality expression data
and histopathologic information.
Data processing and normalization
First, flagged intensities and probes with signal to noise ratio
below 3 were removed from the raw data. Next, the number of
probes was further reduced to 17910, by removing those that had
missing values in more that 80% of the samples. The quantile
normalization procedure was applied using ABarray library in R
and the missing values were imputed using the k-nearest neighbors
algorithm of the smida library in R. After re-scaling the expression
Weighted Gene Expression
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applied. Data is accessible at NCBI GEO database accession
GSE24117.
Statistical analysis
Across the whole dataset, the percentages of stroma cell area
varied from 5% to 85%, for tumor cells; from 5% to 85%, and for
adipocytes; from 0% to 50%. A two-sample Kolmogorov-Smirnov
test was used to compare the distribution of the different cell types
in the DM and NoDM groups [37].
To incorporate the information on cell type abundance into the
testing procedure, the tumor-weighted or stroma-weighted mean
expression of the gene was computed instead of the arithmetic mean,
for both groups of patients (DM and NoDM) as   X XDM~
P
i[DM wiXi P
i[DM wi
and XNoDM~
P
j[NoDM wjXj
P
j[NoDM wj
where the sums go over all samples in
each cohort and the weight wi and wj i st h em e a np e r c e n t a g e( a v e r a g e
of the two sections per sample) of area covered by tumor (or stroma)
in the sample. The difference of the means was taken and
standardized giving the statistics tw~
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NoDM, being the estimated variances of the respective
cohorts and nDM,nNoDM their sizes. The p-values were computed by
performing permutation test and after a 5% FDR adjustment for
multiple testing, different sets of differentially expressed genes (DEGs)
between the two cohorts were identified. The un-weighted analysis
was performed by setting the weights to 1 which is equivalent the
standard t-test with equal variances.
The tumor-focused and the stroma-focused analyses were
carried out under various assumptions. In the first series of
analyses we assumed that the total gene transcription of the three
tissue components (tumor, stroma and adipocytes) occurred at an
equal level. However, due to uncertainty around the transcription
level of adipose tissue, the weighted analysis was repeated for
various relative efficiencies (c) of transcription of adipocytes
compared to tumor cells. For different values of c ranging from 0
to 1, the adipocytes percentage area (a) was scaled to ac and the
percentages of area covered by tumor and stroma were re-scaled
so that they summed up to 100. The re-scaled tumor (t9) and
stroma (s9) weights were computed as t9=t/(t+s+ac) and s9=s/
(t+s+ac), where t, s and a are respectively, tumor, stromal and
adipocyte cell area proportions in the original data and c the
relative level of transcription of adipocytes compared to the other
two tissue components.
The analyses carried out for the other selected values of c gave
different sets of genes, differentially expressed between patients
who developed distance metastasis and those who did not. In both
series of analyses (tumor-weighted and stroma-weighted, for
different levels of c), some genes seemed to be consistently
differentially expressed regardless of the assumption on the level of
transcription of adipocytes. Next, the level of transcription of the
adipocytes was set to zero and the cell type-weighted analysis was
performed under different assumptions on the level of transcrip-
tion d of stroma cells compared to tumor cells. Analogous to the
first series of analyses, for each level of d the percentages of area
covered by tumor and stroma were re-scaled to sum up to 1. These
new weights were computed ad t0=t9/(t9+s9d) and s0=(t9+s9)2t0.
Validation data
Gene expression data and associated clinical information on
metastatic disease were available from microdissected tumor
stroma and tumor epithelium from patients with invasive ductal
carcinoma [15]. The tumor epithelial dataset included 61 patients
with either distant metastatic disease (16) or no local or distant
metastatic disease (45); the tumor-stroma dataset included 50
patients with either distant metastatic disease (10) or no local or
distant metastatic disease (40). (Out of the 50 patients with
available tumor-stroma gene expression two patients were not
among the 61 with available tumor-epithelial expression data).
The samples in the validation set had been analyzed on Agilent
Whole Human Genome 44K arrays and hence, probes were
matched between the Applied Biosystem whole genome survey
microarrays and the Agilent platform by gene symbols. For genes
being represented by more than one probe, the probe that
matched the target RefSeqs was selected. In cases where multiple
probes matched the RefSeq, the probe with highest variance
across the sample cohort was selected. Out of the 99 DEGs in
SACsev and TACsev combined, we were able to identify 74
matching genes in the validation set (24 out of 31 DEGs in SACsev
and 69 out of 94 DEGs in TACsev) (Table S5 and S6).
Supporting Information
Figure S1 RNA extraction. Fresh-frozen tumor piece cut in
three, a, b and c. Sections cut from pieces a and c for pathological
estimation of area percentages of adipocytes, stromal cells and
carcinoma cells. Centre piece b was used for total RNA extraction
and microarray analyses.
Found at: doi:10.1371/journal.pone.0014002.s001 (0.27 MB
PDF)
Table S1 Genes associated with tumor epithelial and stromal
expression. List of genes (Gene symbol and Celera Gene ID) with
reported cell type association in literature, were compared to the
fold change (and local FDR) from a SAM analysis between the 15
samples with the highest tumor cell percentage and the 15 samples
with the highest stroma cell percentage. The Pearson correlations
(and p-value) for each gene to the tumor and stroma cell
percentage across all 198 samples are also included.
Found at: doi:10.1371/journal.pone.0014002.s002 (0.04 MB
XLS)
Table S2 UWA geneprobe list. List of DEGs from the
unweighted analysis, 182 gene-probes differentially expressed in
tumor samples from patients who experienced distant metastasis
compared with those who did not.
Found at: doi:10.1371/journal.pone.0014002.s003 (0.04 MB
XLS)
Table S3 DEGs under various assumptions of d. Lists of all
DEGs found in the various weigthed analyses under different
assumptions of the contribution of mRNA transcription from
stroma.
Found at: doi:10.1371/journal.pone.0014002.s004 (0.10 MB
XLS)
Table S4 Validated DEGs in LCM stroma and tumor epithelial
expression data. List of 74 genes that were matched to the stroma
and tumor epithelial expression validation set. Left columns in the
split table show the original regulation of genes in DM vs. NoDM
found in the stroma and tumor weighted analyses, respectively.
The next column shows the regulation seen in the validation sets
(only for those with a p-value,0.5). The significant differences in
the validation sets are highlighted in red.
Weighted Gene Expression
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XLS)
Table S5 LCM Stroma. List of all gene probes with gene
expression data for the matching 74 genes in the LCM stroma.
Left column annotates no distant metastasis=0 and metastasis=1.
Found at: doi:10.1371/journal.pone.0014002.s006 (0.15 MB
XLS)
Table S6 LCM Epi. List of all gene probes with gene expression
data for the matching 74 genes in the LCM tumor epithelial. Left
column annotates no distant metastasis=0 and metastasis=1.
Found at: doi:10.1371/journal.pone.0014002.s007 (0.18 MB
XLS)
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